Zandelisib

DRUG3 trials

Sponsors

MEI Pharma, Inc., Jacob Soumerai, MD

Conditions

CLLFollicular Lymphoma (FL)Marginal Zone LymphomaNon Hodgkin LymphomaRefractory Follicular LymphomaRelapsed Follicular Lymphoma

Phase 1

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

WithdrawnNCT05604417

Jacob Soumerai, MDRefractory Follicular Lymphoma, Relapsed Follicular Lymphoma

Start: 2023-01-31End: 2026-12-01Updated: 2023-07-07

Phase 2

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

WithdrawnNCT05209308

MEI Pharma, Inc.CLL

Start: 2022-11-22End: 2023-03-15Updated: 2023-03-16

Phase 3

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

TerminatedNCT04745832

MEI Pharma, Inc.Follicular Lymphoma (FL), Marginal Zone Lymphoma, Non Hodgkin Lymphoma

Start: 2021-08-13End: 2023-03-20Updated: 2024-11-04

Related Papers

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Blood2022-11-155 citations

S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

HemaSphere2022-06-01

Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Blood2021-11-055 citations

COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)

Hematological Oncology2021-06-01

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

Journal of Clinical Oncology2021-05-202 citations